Endo International plc - Ordinary Shares (ENDP): Price and Financial Metrics

Endo International plc - Ordinary Shares (ENDP): $3.38

0.37 (+12.29%)

POWR Rating

Component Grades














  • ENDP scores best on the Value dimension, with a Value rank ahead of 99.82% of US stocks.
  • ENDP's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • ENDP's current lowest rank is in the Sentiment metric (where it is better than 10.6% of US stocks).

ENDP Stock Summary

  • Endo International plc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 2.17% of US listed stocks.
  • With a price/sales ratio of 0.25, Endo International plc has a higher such ratio than merely 3.87% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -13.93 for Endo International plc; that's greater than it is for just 1.27% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Endo International plc are CCJ, DBD, IGT, ASH, and BKYI.
  • ENDP's SEC filings can be seen here. And to visit Endo International plc's official web site, go to www.endo.com.

ENDP Valuation Summary

  • ENDP's price/sales ratio is 0.2; this is 98.24% lower than that of the median Healthcare stock.
  • ENDP's EV/EBIT ratio has moved up 23.1 over the prior 243 months.
  • ENDP's price/sales ratio has moved down 4 over the prior 243 months.

Below are key valuation metrics over time for ENDP.

Stock Date P/S P/B P/E EV/EBIT
ENDP 2021-08-31 0.2 -0.9 7.7 14.9
ENDP 2021-08-30 0.2 -0.9 7.7 14.9
ENDP 2021-08-27 0.2 -0.9 7.8 14.9
ENDP 2021-08-26 0.2 -0.9 8.1 14.9
ENDP 2021-08-25 0.2 -1.0 8.5 15.0
ENDP 2021-08-24 0.2 -1.0 8.9 15.0

ENDP Growth Metrics

  • Its 3 year cash and equivalents growth rate is now at 76.67%.
  • The 4 year revenue growth rate now stands at -14.32%.
  • Its 4 year price growth rate is now at -74.27%.
Over the past 15 months, ENDP's revenue has gone down $187,528,000.

The table below shows ENDP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 2,826.83 429.32 69.48
2021-03-31 2,800.588 578.676 95.538
2020-12-31 2,903.074 397.392 183.944
2020-09-30 2,907.653 268.251 -154.042
2020-06-30 3,002.219 378.338 -157.57
2020-03-31 3,014.358 251.191 -274.133

ENDP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ENDP has a Quality Grade of C, ranking ahead of 35.2% of graded US stocks.
  • ENDP's asset turnover comes in at 0.307 -- ranking 150th of 677 Pharmaceutical Products stocks.
  • CEMI, CDXC, and HSKA are the stocks whose asset turnover ratios are most correlated with ENDP.

The table below shows ENDP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.307 0.525 0.057
2021-03-31 0.304 0.515 0.058
2020-12-31 0.315 0.503 0.051
2020-09-30 0.314 0.493 0.028
2020-06-30 0.319 0.496 0.029
2020-03-31 0.312 0.480 0.016

ENDP Price Target

For more insight on analysts targets of ENDP, see our ENDP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.57 Average Broker Recommendation 2 (Hold)

ENDP Stock Price Chart Interactive Chart >

Price chart for ENDP

ENDP Price/Volume Stats

Current price $3.38 52-week high $10.89
Prev. close $3.01 52-week low $1.94
Day low $2.98 Volume 14,519,297
Day high $3.39 Avg. volume 6,440,642
50-day MA $3.47 Dividend yield N/A
200-day MA $5.83 Market Cap 789.23M

Endo International plc - Ordinary Shares (ENDP) Company Bio

Endo International plc focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The company was founded in 1920 and is based in Dublin, Ireland.

ENDP Latest News Stream

Event/Time News Detail
Loading, please wait...

ENDP Latest Social Stream

Loading social stream, please wait...

View Full ENDP Social Stream

Latest ENDP News From Around the Web

Below are the latest news stories about Endo International plc that investors may wish to consider to help them evaluate ENDP as an investment opportunity.

Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States

Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the generic version of Pfizer's Chantix® (varenicline), 0.5 mg and 1 mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

Yahoo | September 22, 2021

Endo (ENDP) Gains on Settlement of Opioid Cases in New York for $50M

Endo (ENDP) stock gains following the settlement of three opioid cases in the New York State in exchange for a total payment of $50 million.

Yahoo | September 13, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're back at it again with one last day of trading this week and we're kicking it off with Friday's biggest pre-market stock movers.

William White on InvestorPlace | September 10, 2021

Endo Bonds Jump After N.Y. Opioid Settlement Heads Off Threats

(Bloomberg) -- Endo International Plc’s debt rallied on Friday after the company settled claims by New York over its opioid marketing, averting a possible $1 billion verdict and the risk it could have been stripped of its legal defenses in an ongoing trial in the state. The pact, announced late Thursday, settles for $50 million allegations that the opioid maker’s sales and marketing efforts helped fuel a public crisis over the highly addictive painkillers. Lawyers for New York Attorney General L

Yahoo | September 10, 2021

41 Stocks Moving In Friday's Mid-Day Session

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic atrophy. IVERIC Bio, a competitor to Apellis, is also working on a product to treat geographic atrophy, called Zimura. Stifel initiated coverage on IVERIC bio with a Buy rating and announced a price target of $22. Echo Global Logistics, Inc. (NASDAQ: ECHO) surged 53.8% to $48.16 after the company agreed to be acquired by priva

Yahoo | September 10, 2021

Read More 'ENDP' Stories Here

ENDP Price Returns

1-mo 28.03%
3-mo -31.30%
6-mo -56.39%
1-year 10.28%
3-year -79.25%
5-year -85.55%
YTD -52.92%
2020 53.09%
2019 -35.75%
2018 -5.81%
2017 -52.94%
2016 -73.10%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0176 seconds.